Gastrointestinal side effects of paromomycin (the active ingredient contained in Humatin) have commonly included nausea, vomiting, diarrhea, and abdominal discomfort, especially with doses greater than  g per day.
Malabsorption of xylose and sucrose has been reported.
A case of pancreatitis in an AIDS patient has been attributed to paromomycin.
A patient with AIDS developed pancreatitis after five days of therapy with paromomycin for cryptosporidiosis.
Serum amylase declined progressively after paromomycin was discontinued, but became elevated after reinstitution of therapy.
Nervous system side effects have rarely included ototoxicity and sensorineural damage, usually in patients who also had hepatic disease.
Rarely, patients may also experience headache or vertigo.
Nephrotoxicity is a consideration with the use of any aminoglycoside, however, paromomycin (the active ingredient contained in Humatin) is poorly absorbed by the gastrointestinal tract.
Accumulation of paromomycin may be problematic in patients with impaired renal function and patients treated with multiple or prolonged courses of therapy.
Hepatic side effects have included transient elevated aspartate transaminase (greater than  times ULN) and alanine transaminase (greater than  times ULN) in patients receiving intramuscular paromomycin (the active ingredient contained in Humatin) during a clinical study.
Local side effects have included injection site pain and swelling in patients receiving intramuscular paromomycin (the active ingredient contained in Humatin) during a clinical study.
Other side effects have included pyrexia in patients receiving intramuscular paromomycin (the active ingredient contained in Humatin) during a clinical study.
Abdominal or stomach cramps
diarrhea
nausea